文献速递消化系统肿瘤泌尿男性生殖肿瘤骨软组织肉瘤与黑色素瘤

已发表肿瘤篮式试验的汇总分析

A pooled analysis of published, basket trials in cancer medicine.
PubMed 文献 · Eur J Cancer · 2018-08-07

该研究系统检索并汇总分析了已发表的肿瘤篮式试验,共纳入8篇文章、1176例患者,覆盖超过33种肿瘤类型。总体缓解率为25%,卵巢癌和输卵管癌、结直肠癌和肉瘤是最常见的瘤种,而常见肿瘤相对于罕见肿瘤可能在篮式试验中被低估。

要点

  • 已发表篮式试验共纳入1176例患者,覆盖超过33种肿瘤类型
  • 总体缓解率为25%,多数患者未获缓解
  • 常见肿瘤相对于罕见肿瘤可能在篮式试验中被低估

核心结论

  • 已发表篮式试验累计纳入超过1100例患者,总体缓解率为25%,常见肿瘤相对于罕见肿瘤可能被低估。
  • 入组篮式试验的患者应被告知,尽管这类研究前景很好,但多数患者并未缓解。

研究设计与样本

  • 系统综述,纳入不限制肿瘤类型、以生物标志物作为入组依据、前瞻性给予至少一种抗肿瘤药物并按瘤种报告缓解情况的已发表篮式试验。
  • 共纳入8篇文章,合计入组1176例患者,覆盖超过33种肿瘤类型。
  • 利用国家癌症统计数据识别篮式试验中过度代表和代表性不足的肿瘤类型。

主要发现

  • 卵巢癌和输卵管癌221/1176(19%)、结直肠癌144/1176(12%)、肉瘤129例(11%)是最常见的瘤种。
  • 肾细胞癌、精原细胞瘤、胸腺癌、神经内分泌肿瘤和阑尾癌代表性最低,各仅1例。
  • 总体缓解率为25%。
  • 常见肿瘤相比罕见肿瘤可能被低估:线性回归beta=0.58,95%CI=-0.037-1.21(斜率<1提示低估,>1提示过度代表)。

临床怎么用

  • 向拟入组篮式试验的患者说明:这类研究虽前景可期,但总体缓解率约25%,多数患者不会缓解。
  • 关注常见肿瘤在篮式试验中代表性可能不足的问题,并在试验设计与入组时加以考虑。

局限性

  • 仅纳入已发表的篮式试验,可能存在发表偏倚。
  • 样本量为8篇文章、1176例患者,覆盖瘤种虽多但部分瘤种仅1例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is widespread interest in cancer basket trials. However, to date, there has been no formal analysis of all published basket trials. METHODS: We performed a systematic review to identify all published basket trials in cancer medicine. We included studies that (1) did not place restriction on tumour type and (2) used a biomarker for the basis of enrolment (3) administered at least one anti-cancer agent in prospective fashion and (4) reported responses by each tumour type included. We sought information regarding the tumour histology included and the response rate in basket trials. In addition, we used national cancer statistics to identify which tumour types have been overrepresented in basket studies (i.e. more representation in trials than their incidence would suggest) and those which are under-represented. RESULTS: We identified eight articles with a combined enrolment of 1176 patients were included in our analysis, representing over 33 tumour types. Ovarian and fallopian tube cancers 221/1176 (19%), colorectal cancer 144/1176 (12%) and sarcoma 129 (11%) were the most common tumours represented, whereas renal cell cancer, seminoma, thymic carcinoma and neuroendocrine tumour and appendiceal carcinoma were the least represented with one case each. The overall response rate was 25%. Common cancers may be underrepresented compared with rarer tumour types (linear regression beta = 0.58, 95% confidence interval = -0.037-1.21) (slope < 1 implies under-representation, >1 over-representation). CONCLUSIONS: We found that, to date, over 1100 patients have been enrolled on published basket studies. Common cancers may be underrepresented compared with rarer tumours. The overall response rate was 25%. Patients enrolling on basket trials should be counselled appropriately that although these studies are highly promising, most patients did not respond. Future targets and drugs may improve on these results.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hazim A, Prasad V. A pooled analysis of published, basket trials in cancer medicine. Eur J Cancer. 2018. PMID: 30096705. doi:10.1016/j.ejca.2018.06.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。